Compare RCMT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | IPHA |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 160.7M |
| IPO Year | 1997 | N/A |
| Metric | RCMT | IPHA |
|---|---|---|
| Price | $18.85 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $5.75 |
| AVG Volume (30 Days) | ★ 36.6K | 12.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $16.29 | $28.31 |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $14.58 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $14.83 | $1.40 |
| 52 Week High | $28.19 | $2.63 |
| Indicator | RCMT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 31.04 |
| Support Level | $19.02 | N/A |
| Resistance Level | $21.00 | $1.88 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 47.87 | 2.53 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.